Article info
Clinical and epidemiological research
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
- Correspondence to Dr Nicolino Ruperto, Clinica Pediatrica e Reumatologia, PRINTO, Istituto G. Gaslini, Genova 16147, Italy; nicolaruperto{at}gaslini.org
Citation
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Publication history
- Received February 1, 2018
- Revised July 20, 2018
- Accepted August 6, 2018
- First published September 29, 2018.
Online issue publication
November 16, 2018
Article Versions
- Previous version (16 November 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/